Camurus AB

Camurus AB

Health CarePharmaceuticals & Biotechnology
  • Price (SEK)67.00
  • Today's Change3.60 / 5.68%
  • Shares traded124.61k
  • 1 Year change-53.02%
  • Beta--
Data delayed at least 15 minutes, as of Jan 18 2019 17:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.

  • Revenue in SEK (TTM)46.97m
  • Net income in SEK-199.72m
  • Incorporated--
  • Employees81.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Calliditas Therapeutics AB0.00-128.37m1.51bn10.00--2.42-----4.36-4.360.0018.740.00----0.00-35.91---38.23-------------1,379.310.00-------52.51------
Alligator Bioscience AB52.66m-106.94m1.53bn53.00--3.06--29.01-1.50-1.500.73776.990.0914--22.411,120,511.00-18.56---19.37---114.25---203.06------0.00---2.34---31.85------
Bergenbio ASA0.00-198.66m1.55bn24.00--3.78-----3.67-3.670.007.090.00----0.00-44.91---48.04--------------0.00-------40.38------
Infant Bacterial Therapeutics AB0.00-25.52m1.64bn----2.93-----3.16-3.160.0051.740.00-------7.59-25.10-7.74-26.89-------18,575.38---26.650.00--46.91--5.12------
Oasmia Pharmaceutical AB1.79m-153.28m1.91bn57.00--5.28--1,070.58-0.9064-0.90640.01061.800.0031-0.53561.0530,775.86-26.27-25.38-37.11-39.72460.62591.85-8,587.68-5,423.880.574-5.660.2353--1,742.44--26.36---19.03--
Orexo AB747.10m113.20m2.41bn102.0021.615.6918.,301,111.0010.10-7.7221.47-11.5576.0879.9415.15-12.331.7818.300.43---8.8114.56-20.00---22.62--
Immunovia AB (publ)267.96k-76.20m2.46bn45.00--5.69--9,177.36-4.24-4.240.014924.970.0007--0.03877,881.18-20.01---20.60---11,463.52---28,437.53------0.00---15.97---207.22------
Camurus AB46.97m-199.72m2.57bn81.00--7.57--54.74-5.32-5.321.258.850.09770.70413.48661,605.60-41.53---51.45--92.25---425.17--2.48--0.00---52.25---135.30------
Nordic Nanovector ASA52.75k-353.38m2.74bn40.00--5.86--51,893.64-6.83-6.830.0018.960.00007--0.00181,351.35-48.95-29.75-55.47-32.41-----669,926.00-43,551.55----0.00---3.8215.31-24.76--100.25--
IRLAB Therapeutics AB15.00k-68.48m2.76bn19.00--12.06--184,117.70-9.30-9.300.00228.530.00007--0.0035681.82-32.11---34.32---333,453.30---456,540.00-----311.700.00---24.31---31.69------
Data as of Jan 18 2019. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK

Institutional shareholders

17.95%Per cent of shares held by top holders
HolderShares% Held
Max Mitteregger Kapitalf�rvaltning ABas of 03 Dec 20182.49m6.48%
SEB Investment Management ABas of 31 Dec 2017951.27k2.48%
Catella Fondf�rvaltning ABas of 31 Dec 2018915.65k2.39%
Fj�rde AP-fondenas of 31 Dec 2017797.73k2.08%
Swedbank Robur Fonder ABas of 31 Dec 2018706.46k1.84%
Enter Fonder ABas of 31 Dec 2017682.87k1.78%
Xact Kapitalf�rvaltning ABas of 31 Dec 2018179.94k0.47%
Andra AP-fondenas of 30 Jun 2018144.69k0.38%
Skandia Investment Management ABas of 30 Nov 201813.93k0.04%
Danske Bank A/S (Investment Management Sweden)as of 17 Jan 201910.47k0.03%
More ▼
Data from 31 Dec 2016 - 18 Jan 2019Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.